FAG
VRTX icon

Fortitude Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Fortitude Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-317
Closed -$83K – 1272
2022
Q1 		$83K Hold
317
– – 0.04% 392
2021
Q4 		$70K Buy
+317
New +$61.6K 0.04% 446

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fortitude Advisory Group's VRTX Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 317 shares — an estimated $83K sold.

Fortitude Advisory Group first reported a position in VRTX in Q4 2021 and held it in 2 quarters. The position peaked at $83K in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 317 Vertex Pharmaceuticals shares in Q2 2022, an estimated $83K.
  • Fortitude Advisory Group first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Vertex Pharmaceuticals position peaked at $83K in Q1 2022.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.